Abstract

Purpose: To translate a recombinant peptide containing the amino-terminal fragment (ATF)of urokinase plasminogen activator receptor-targeted magnetic iron oxide (IO) nanoparticles(uPAR-targeted human ATF-IONPs) into clinical applications, we conducted a pilot study to evaluate the toxicity and pharmacokinetics of this nanoparticle in normal rhesus monkeys.

Keywords: uPAR-IONP, nonhuman primates, Transient harm, Self-healing

Fig.1. The MRI signal alterations in liver and spleen.

Notes: (A and B) are the MRI images before and after ATF-IONP injection, respectively, without and with PEG coating, both of them are phased from up to down. (C and D) are the variations of T2 signal intensity; (E and F) are the variations of T1 signal intensity. Monkey 1 received ATF-IONP, and Monkey 2 received ATF-PEG-IONP.Abbreviations: ATF, amino-terminal fragment; IONP, magnetic iron oxide nanoparticle; MRI, magnetic resonance imaging; PEG, polyethylene glycol.

Link to this article